ABSTRACT
INTRODUCTION
Diabetes is one of the leading cause of mortality and morbidity throughout the globe. 1 In the recent years, the prevalence of type 2 diabetes has been on the rise in India with an average prevalence of 9.1% observed in 2013. 2 Moreover, diabetes exerts a significant financial burden on the individuals, healthcare system, and the society due to chronicity of the nature of the disease. 3 The cornerstone of management of diabetes is primarily the glucose-lowering therapies. 4 Therefore, the healthcare professional organizations have laid guidelines for the stringent metabolic targets as the principle for diabetes management. [5] [6] Presently, there are eleven different classes of hypoglycemic agents along with numerous insulin preparations available as a treatment option for type 2 diabetes. 7 The confirmatory diagnosis of type 2 diabetes consists of HbA 1C ≥ 6.5% along with fasting plasma glucose (FPG) ≥ 126 mg/dL and postprandial blood glucose (PPBG) ≥ 200 mg/dL. If HbA 1C is ≥ 7.5% at the time of diagnosis, it is advised to initiate pharmacological treatment with the oral hypoglycemic agent, i.e. metformin. [8] [9] Whereas, insulin is started at first for the symptomatic patients presenting with markedly elevated HbA 1C and later can be switched to metformin. 10 When to initiate second-line agents is still under discrepancy and there is no clear guideline in this regard. Nevertheless, it is stated that if the target HbA 1C is not achieved over a span of 3 months of treatment initiation; it is advised to add a second oral hypoglycemic agent or a glucagon-like peptide 1 (GLP-1) receptor agonists or a basal insulin.
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Metformin remains as the first line agent for type 2 diabetes management. 12 There is no consensus to support the use of one second-line agent over the other. 13 Due to the emergence of safety concerns with regards to stroke, heart failure, myocardial infarction, bladder cancer, and bone fractures; a decline was seen in the utilization pattern of rosiglitazone and pioglitazone after 2006 and 2011 respectively. [14] [15] Dual or triple combination therapy having complementary mechanisms of action is not only essential but also logical and necessary to achieve glycemic targets. 16 Henceforth, in view of the limited Indian data, the present study was designed and aimed to investigate: (a) the utilization pattern of second-line agents; (b) analyze the indications for their initiation, and (c) the outcome analysis of combination therapies.
MATERIALS AND METHODS
This study was designed as a descriptive retrospective study, conducted 
Statistical Analysis
SPSS software version 16.0 was used for data analysis. The descriptive statistics i.e., mean ± standard deviation, median, interquartile range, number, and percentage were used to describe the data. The repeated measures analysis of variance (ANOVA) was used to analyze the primary parameters at three-time intervals i.e., at baseline, 3 rd month, and 6 th month for respective groups. The p-value < 0.05 was considered as statistically significant.
RESULTS
The study population consisted of 135 males (56.3%) and 105 females (43.8%). The mean age of the subjects was 56.79±11.73 years, ranging from 21-87 years. The demographic details of the study population have been described in [ Table 1 ]. Metformin was the most commonly prescribed first-line antihyperglycemic agent followed by glimepiride and glibenclamide. The average dose of previous anti-diabetic medications was: glibenclamide 6.18 mg/day, glipizide 9.8 mg/day, gliclazide 97.33 mg/day, glimepiride 6.16 mg/day, and metformin 1267 mg/day. The number of patients utilizing the second-line add-on agents was 54, 68, 52, and 66 in pioglitazone, DPP-4 inhibitor, voglibose, and insulin group respectively. The pattern of antidiabetic drug use amongst the study population with duration of diabetes has been depicted in [ Figure 1 ]. The pattern of various combination therapies has been summarized in [ Figure 2 ]. The average dose of second-line add-on agents used daily was pioglitazone 17.88 mg, sitagliptin 52.70 mg, vildagliptin 50 mg, voglibose 0.29 mg respectively. Insulin was used at a mean dose of 24.86, 15.11 and 16.23 units/day in the morning, afternoon and night respectively. The baseline characteristics of the study population have been described in [ Table 2 ]. The mean HbA 1C observed was 9.99% with standard deviation (SD) of 2.43%. The mean FPG and PPBG of the subjects was 218±78.20 mg/dL and 305.64±106.14 mg/dL respectively. The most common reason to initiate add-on therapy was uncontrolled type 2 diabetes measured as the high glycemic index in all respective groups. Though, the other leading causes were morbid obesity and dyslipidemia; infections and poor compliance with oral hypoglycemic agents lead to the initiation of insulin therapy as shown in [ Figure 3 has been summarized in [ Table 3 , 4] and was statistically significant (p-value < 0.001) within each group at 3 and 6 months respectively.
DISCUSSION
The present study aimed at investigating the utilization pattern of second-line agents as well as analyzing the outcome of treatment in terms of effectiveness of various second-line agents added for the first time to previously prescribed metformin or sulfonylureas or a combination of both. From 2003-2012 in the USA, the scenario of antidiabetic drug utilization had shown that 44.9% prescriptions had metformin monotherapy, pioglitazone prescription rates were nearly constant and rosiglitazone usage drastically declined. At the same time, newer approved drugs such as DPP-4 inhibitors were on a steady rise occupying 22% share. 17 From 2008-2013 in Taiwan, DPP-4 inhibitors were the most prescribed agent for adjunctive therapy. 18 In our findings from the year 2014, prescription of DPP-4 inhibitor had an increased share of 28.3%. The upsurge in the trend towards DPP-4 inhibitor can be attributed to simple dosing regimen, oral administration, lesser adverse effects, better tolerability, insignificant hypoglycemic episodes, negligible weight alterations, and a desirable glycemic target achievement. 19 The pioglitazone usage was reported more between 2012-2014 in the study undertaken and contributed to 22.5% prescriptions among second-line agents. The usage of pre-mixed insulin (30% regular/70% NPH) was reported as 27.5% compared to a study conducted in Shimoga district of Karnataka (28.57%). 20 The voglibose prescriptions were 21.7% that is commensurable to a Taiwan study focusing on α-glucosidase inhibitors usage (19.21%). 21 Metformin was the most commonly prescribed first-line antihyperglycemic agent followed by glimepiride and glibenclamide. Among sulfonylureas the least prescribed one was gliclazide. The median duration of diabetes was observed as 8 and 10 years respectively for adding pioglitazone and DPP-4 inhibitor. Hanefeld et al.
showed the mean duration of diabetes to add pioglitazone as 7 years. 22 The research studies have reported the mean duration of diabetes as 6.8 to 7.3 years for adding DPP-4 inhibitors. Our study identified the median duration of diabetes on a higher side in the group 2 probably due to increased availability and upsurge in popularity of DPP-4 inhibitors in India after 2011. It was identified that the maximum number of patients i.e. 28 were prescribed voglibose as the most common second-line agent in those having received antihyperglycemic treatment for past 5 years. Insulin was the most prevalent second-line agent to be added to those receiving first-line drugs for past 10-20 years; while Riddle et al. study had 9.3 years for initiating NPH insulin. 23 It depicts that the early stage of diabetes can be well managed by dual or triple oral hypoglycemic agent combination; while on the other hand, the elevated blood glucose levels seen in advanced diabetic stage require intensive insulin therapy. In general, the glycemic control deteriorates in the first 3-5 years and HbA 1C levels increase at an average rate of 0.2-0.3% per year. Usually, the intensive monotherapy fails within 6 years of the initiation of antidiabetic agents. Even the patients who respond well to the monotherapy subsequently fail at a rate of ≥ 5% per year. Therefore, for the secondline agents to be effective, they should work either as insulin sensitizer e.g. pioglitazone or improve insulin resistance e.g. voglibose, sitagliptin, vildagliptin. Eventually, insulin therapy is commenced if drugs acting via either mechanism fail to produce effective results in terms of reducing or maintaining the HbA 1C levels. 24 In the pioglitazone treatment group, the mean difference in HbA 1C at 3 rd and 6 th month with respect to baseline was 1.32±0.72 and 2.11±0.97 respectively which was significant with p-value < 0.001 at each time interval; a greater decline in HbA 1C at 6 th month. Usually, TZDs cause a decline in HbA 1C by 1-1.5% within 12 weeks which matched our finding; while 1.88% mean decline in HbA 1C at 3 rd month was observed by Al-Azzam et al. 25 A systematic review covering pioglitazone combination studies 26 The FPG in pioglitazone add-on group exhibited a mean decrease of 60 and 75 mg/dL at 3 rd and 6 th month respectively from the baseline which was significant (p < 0.001) at both the time intervals. Previously conducted 12-week and 16-week pioglitazone add-on studies demonstrated a decline of 38 mg/dL and 20.5 mg/dL respectively in FPG. 27 The present study observed a mean decline of 1.19±0. 27 30 In present voglibose treatment group a mean reduction of 83.98 and 118.75 mg/dL in PPBG at 3 and 6 months respectively which was statistically significant.
Limitations
The retrospective nature of study design and a smaller sample size were the limitations of this study. Analysis of the trend of second-line agents' prescription over 3-years was not feasible owing to small sample size, restrained study timeframe, and limited resources. A larger sample size could have provided sufficient data to compare the efficacy between the groups at respective time intervals. The parameters were recorded with a window period of ±15-20 days at 3 rd and 6 th month. Sub-group analysis based on the number of glucose-lowering drugs utilized [dual therapy (metformin/sulfonylurea+ second-line agent versus triple therapy (metformin+ sulfonylurea+ second-line agent)] was not carried out.
CONCLUSION
Type 2 DM is a modern pandemic and requires lifelong treatment. Failure to achieve the glycemic target and rapid progression to complications are the main concerns in the management of diabetes. There are various antidiabetic agents available to lower blood glucose levels. There was a gradual shift in trend towards prescribing DPP-4 inhibitors over the recent years. Our study focused on the effectiveness of second-line agents in combination with metformin or sulfonylurea or both. Pioglitazone add-on group had the greatest decline in HbA 1C at 3 rd and 6 th month followed by DPP-4 inhibitor group. All the four add-on groups exhibited a significant reduction in FPG and PPBG when used as dual or triple combination therapy over 3 and 6 months. DPP-4 inhibitor add-on group was found to be safe in terms of least hypoglycemic episodes. Therefore, it can be inferred that DPP-4 inhibitors are modestly effective second-line anti-diabetic agent in uncomplicated type 2 diabetes.
